Advent, Avista Drop $1.5B Drug Co. Buy Amid FDA Scrutiny
Private equity firms Advent International and Avista Capital Partners have dropped their $1.5 billion deal to buy the U.S. generic-drug business of UCB SA, as regulators raise questions about the unit's...To view the full article, register now.
Already a subscriber? Click here to view full article